FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095508261> ?p ?o ?g. }

• W2095508261 abstract "Introduction of calcineurin inhibitors had led to improved survival rates in liver transplant recipients. However, long-term use of calcineurin inhibitors is associated with a higher risk of chronic renal failure, neurotoxicity, de novo malignancies, recurrence of hepatitis C viral (HCV) infection and hepatocellular carcinoma. Several studies have shown that everolimus has the potential to provide protection against viral replication, malignancy, and progression of fibrosis, as well as preventing nephrotoxicity by facilitating calcineurin inhibitor reduction without compromising efficacy. The Hephaistos study evaluates the beneficial effects of early initiation of everolimus in de novo liver transplant recipients. Hephaistos is an ongoing 12-month, multi-center, open-label, controlled study aiming to enroll 330 de novo liver transplant recipients from 15 centers across Germany. Patients are randomized in a 1:1 ratio (7–21 days post-transplantation) to receive everolimus (trough levels 3–8 ng/mL) with reduced tacrolimus (trough levels <5 ng/mL), or standard tacrolimus (trough levels 6–10 ng/mL) after entering a run-in period (3–5 days post-transplantation). In the run-in period, patients are treated with induction therapy, mycophenolate mofetil, tacrolimus, and corticosteroids according to local practice. Randomization is stratified by HCV status and model of end-stage liver disease scores at transplantation. The primary objective of the study is to exhibit superior renal function (estimated glomerular filtration rate assessed by the Modification of Diet in Renal Disease (MDRD)-4 formula) with everolimus plus reduced tacrolimus compared to standard tacrolimus at Month 12. Other objectives are: to assess the incidence of treated biopsy-proven acute rejection, graft loss, or death; the incidences of components of the composite efficacy endpoint; renal function via estimated glomerular filtration rate using various formulae (MDRD-4, Nankivell, Cockcroft-Gault, chronic kidney disease epidemiology collaboration and Hoek formulae); the incidence of proteinuria; the incidence of adverse events and serious adverse events; the incidence and severity of cytomegalovirus and HCV infections and HCV-related fibrosis. This study aims to demonstrate superior renal function, comparable efficacy, and safety in de novo liver transplant recipients receiving everolimus with reduced tacrolimus compared with standard tacrolimus. This study also evaluates the antiviral benefit by early initiation of everolimus. NCT01551212 ." @default.
• W2095508261 created "2016-06-24" @default.
• W2095508261 creator A5001920483 @default.
• W2095508261 creator A5026259194 @default.
• W2095508261 creator A5044825904 @default.
• W2095508261 creator A5051091059 @default.
• W2095508261 creator A5071973338 @default.
• W2095508261 creator A5074329864 @default.
• W2095508261 date "2015-03-26" @default.
• W2095508261 modified "2023-10-16" @default.
• W2095508261 title "Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial" @default.
• W2095508261 cites W1488185656 @default.
• W2095508261 cites W1589012735 @default.
• W2095508261 cites W1591245977 @default.
• W2095508261 cites W1604773174 @default.
• W2095508261 cites W1626176231 @default.
• W2095508261 cites W1712081652 @default.
• W2095508261 cites W1912397813 @default.
• W2095508261 cites W1980200118 @default.
• W2095508261 cites W1981723348 @default.
• W2095508261 cites W1994757982 @default.
• W2095508261 cites W1998803562 @default.
• W2095508261 cites W2004366555 @default.
• W2095508261 cites W2011448791 @default.
• W2095508261 cites W2025458886 @default.
• W2095508261 cites W2028386866 @default.
• W2095508261 cites W2029342078 @default.
• W2095508261 cites W2034886073 @default.
• W2095508261 cites W2055864845 @default.
• W2095508261 cites W2077349622 @default.
• W2095508261 cites W2078198008 @default.
• W2095508261 cites W2080790649 @default.
• W2095508261 cites W2081977398 @default.
• W2095508261 cites W2106529798 @default.
• W2095508261 cites W2109389868 @default.
• W2095508261 cites W2117698357 @default.
• W2095508261 cites W2118463004 @default.
• W2095508261 cites W2134672034 @default.
• W2095508261 cites W2135886861 @default.
• W2095508261 cites W2137515443 @default.
• W2095508261 cites W2409313385 @default.
• W2095508261 cites W4233513120 @default.
• W2095508261 cites W4252564070 @default.
• W2095508261 doi "https://doi.org/10.1186/s13063-015-0626-0" @default.
• W2095508261 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4384314" @default.
• W2095508261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25873064" @default.
• W2095508261 hasPublicationYear "2015" @default.
• W2095508261 type Work @default.
• W2095508261 sameAs 2095508261 @default.
• W2095508261 citedByCount "10" @default.
• W2095508261 countsByYear W20955082612016 @default.
• W2095508261 countsByYear W20955082612017 @default.
• W2095508261 countsByYear W20955082612018 @default.
• W2095508261 countsByYear W20955082612019 @default.
• W2095508261 countsByYear W20955082612021 @default.
• W2095508261 crossrefType "journal-article" @default.
• W2095508261 hasAuthorship W2095508261A5001920483 @default.
• W2095508261 hasAuthorship W2095508261A5026259194 @default.
• W2095508261 hasAuthorship W2095508261A5044825904 @default.
• W2095508261 hasAuthorship W2095508261A5051091059 @default.
• W2095508261 hasAuthorship W2095508261A5071973338 @default.
• W2095508261 hasAuthorship W2095508261A5074329864 @default.
• W2095508261 hasBestOaLocation W20955082611 @default.
• W2095508261 hasConcept C126189478 @default.
• W2095508261 hasConcept C126322002 @default.
• W2095508261 hasConcept C126894567 @default.
• W2095508261 hasConcept C128057223 @default.
• W2095508261 hasConcept C159641895 @default.
• W2095508261 hasConcept C168563851 @default.
• W2095508261 hasConcept C2779609443 @default.
• W2095508261 hasConcept C2779699572 @default.
• W2095508261 hasConcept C2780091579 @default.
• W2095508261 hasConcept C2780303639 @default.
• W2095508261 hasConcept C2909675724 @default.
• W2095508261 hasConcept C2911091166 @default.
• W2095508261 hasConcept C31785415 @default.
• W2095508261 hasConcept C71924100 @default.
• W2095508261 hasConcept C90924648 @default.
• W2095508261 hasConceptScore W2095508261C126189478 @default.
• W2095508261 hasConceptScore W2095508261C126322002 @default.
• W2095508261 hasConceptScore W2095508261C126894567 @default.
• W2095508261 hasConceptScore W2095508261C128057223 @default.
• W2095508261 hasConceptScore W2095508261C159641895 @default.
• W2095508261 hasConceptScore W2095508261C168563851 @default.
• W2095508261 hasConceptScore W2095508261C2779609443 @default.
• W2095508261 hasConceptScore W2095508261C2779699572 @default.
• W2095508261 hasConceptScore W2095508261C2780091579 @default.
• W2095508261 hasConceptScore W2095508261C2780303639 @default.
• W2095508261 hasConceptScore W2095508261C2909675724 @default.
• W2095508261 hasConceptScore W2095508261C2911091166 @default.
• W2095508261 hasConceptScore W2095508261C31785415 @default.
• W2095508261 hasConceptScore W2095508261C71924100 @default.
• W2095508261 hasConceptScore W2095508261C90924648 @default.
• W2095508261 hasIssue "1" @default.
• W2095508261 hasLocation W20955082611 @default.
• W2095508261 hasLocation W20955082612 @default.
• W2095508261 hasLocation W20955082613 @default.
• W2095508261 hasLocation W20955082614 @default.
• W2095508261 hasLocation W20955082615 @default.
• W2095508261 hasOpenAccess W2095508261 @default.

• next